HK1206641A1 - Methods and compositions for treating inflammation - Google Patents

Methods and compositions for treating inflammation

Info

Publication number
HK1206641A1
HK1206641A1 HK15107409.3A HK15107409A HK1206641A1 HK 1206641 A1 HK1206641 A1 HK 1206641A1 HK 15107409 A HK15107409 A HK 15107409A HK 1206641 A1 HK1206641 A1 HK 1206641A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating inflammation
inflammation
treating
Prior art date
Application number
HK15107409.3A
Other languages
English (en)
Chinese (zh)
Inventor
Pedro Santamaria
Original Assignee
Uti Limited Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uti Limited Partnership filed Critical Uti Limited Partnership
Publication of HK1206641A1 publication Critical patent/HK1206641A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15107409.3A 2012-03-26 2015-08-03 Methods and compositions for treating inflammation HK1206641A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615743P 2012-03-26 2012-03-26
PCT/IB2013/052352 WO2013144811A2 (en) 2012-03-26 2013-03-25 Methods and compositions for treating inflammation

Publications (1)

Publication Number Publication Date
HK1206641A1 true HK1206641A1 (en) 2016-01-15

Family

ID=48444453

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107409.3A HK1206641A1 (en) 2012-03-26 2015-08-03 Methods and compositions for treating inflammation

Country Status (15)

Country Link
US (2) US10988516B2 (ru)
EP (2) EP2830654B8 (ru)
JP (3) JP6199955B2 (ru)
CN (2) CN104321077A (ru)
AU (2) AU2013202911A1 (ru)
CA (1) CA2868551C (ru)
DK (1) DK2830654T3 (ru)
ES (1) ES2744491T3 (ru)
HK (1) HK1206641A1 (ru)
IL (2) IL234829B (ru)
MX (1) MX363000B (ru)
PL (1) PL2830654T3 (ru)
PT (1) PT2830654T (ru)
RU (1) RU2689563C2 (ru)
WO (1) WO2013144811A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
JP6427278B2 (ja) * 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ ｐｉｒｉｎポリペプチド及び免疫モジュレーション
US12011480B2 (en) * 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
IL255944B (en) * 2015-05-27 2022-07-01 Univ Northwestern Carbohydrate-modified particles and particle compositions for immune response modulation
EP3303635B1 (en) 2015-06-01 2021-09-01 California Institute of Technology Compositions and methods for screening t cells with antigens for specific populations
US20200390856A1 (en) * 2017-11-29 2020-12-17 Uti Limited Partnership Methods of treating autoimmune disease
BE1026147B1 (nl) * 2018-03-29 2019-10-28 Farm@Nutrition Besloten Vennootschap Met Beperkte Aansprakelijkheid Samenstelling voor een voedingsadditief voor dieren en werkwijze om het additief toe te dienen.
CN116790402B (zh) * 2023-01-14 2024-05-14 西北农林科技大学 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用
WO2024168055A1 (en) * 2023-02-08 2024-08-15 Navigen, Inc. Tnf-alpha binding agents and methods of using the same

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4478946A (en) 1981-07-02 1984-10-23 South African Inventions Development Corporation Carrier bound immunosorbent
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US5171582A (en) 1985-07-31 1992-12-15 Ghent William R Treatment of iodine deficiency diseases
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US4859839A (en) 1988-07-08 1989-08-22 Counter Computer Corporation Point-of-sale terminal for laundry or dry cleaning establishments
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
EP0630255B1 (en) 1991-04-23 2002-12-18 Anergen, Inc. Mhc conjugates useful in ameliorating autoimmunity
US5200189A (en) 1991-07-23 1993-04-06 Ecolab Inc. Peroxyacid antimicrobial composition
WO1993016725A1 (en) 1992-02-27 1993-09-02 The Board Of Trustees Of The Leland Stanford Junior University Early antigen for autoimmune diabetes
JP2631436B2 (ja) 1992-07-24 1997-07-16 徳厚 小島 排水立て管継手
US5972336A (en) 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
CA2185810A1 (en) 1994-03-28 1995-10-05 Jo Klaveness Liposomes
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19508058A1 (de) 1995-02-21 1996-08-22 Schering Ag Verfahren zur Herstellung von DTPA-Tetraestern der terminalen Carbonsäuren und deren Verwendung zur Herstellung pharmazeutischer Mittel
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6033864A (en) * 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
WO1998006749A2 (en) 1996-08-16 1998-02-19 President And Fellows Of Harvard College Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
JP2002504342A (ja) 1998-02-19 2002-02-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
CA2328108A1 (en) 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
DE19825371A1 (de) 1998-06-06 1999-12-09 Bayer Ag Elektrochrome Anzeigevorrichtung mit isolierten Zuleitungen
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
JP2000213425A (ja) 1999-01-20 2000-08-02 Hino Motors Ltd Ｅｇｒク―ラ
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
EP1181053A2 (en) 1999-05-06 2002-02-27 Genetics Institute, Inc. Use of soluble costimulatory molecules to enhance immune responses
CA2386377A1 (en) 1999-10-06 2001-04-12 The Trustees Of The University Of Pennsylvania Cell targeting compositions and methods of using the same
US6585947B1 (en) 1999-10-22 2003-07-01 The Board Of Trustess Of The University Of Illinois Method for producing silicon nanoparticles
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
CA2440474A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
DE10117858A1 (de) 2001-04-10 2002-10-24 Gsf Forschungszentrum Umwelt MHC-Tetramere
JP2004532896A (ja) 2001-06-22 2004-10-28 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｉ型糖尿病の診断及び治療
US20070129307A1 (en) 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
US7332586B2 (en) 2001-07-10 2008-02-19 North Carolina State University Nanoparticle delivery vehicle
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
EP2224012B1 (en) * 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US6688494B2 (en) 2001-12-20 2004-02-10 Cima Nanotech, Inc. Process for the manufacture of metal nanoparticle
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
ATE483469T1 (de) 2002-07-12 2010-10-15 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
DE10310261A1 (de) 2003-03-05 2004-09-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Identifizierung von Antigen-Epitopen
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US6929675B1 (en) 2003-04-24 2005-08-16 Sandia Corporation Synthesis metal nanoparticle
US20050118102A1 (en) 2003-04-28 2005-06-02 Intematix Corporation Spin resonance heating and/or imaging in medical applications
MXPA05012080A (es) 2003-05-08 2006-02-22 Xcyte Therapies Inc Generacion y aislamiento de celulas t especificas al antigeno.
JP2006525813A (ja) 2003-05-20 2006-11-16 イェシバ・ユニバーシティ １型糖尿病において罹患性病原性ｔ細胞により標的とされる抗原ならびにこれの使用
US7060121B2 (en) 2003-06-25 2006-06-13 Hsing Kuang Lin Method of producing gold nanoparticle
WO2005007673A2 (en) 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
GB0321937D0 (en) 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
CA2540633C (en) 2003-10-09 2012-12-04 Emerson Electric Co. Valve assembly
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2005326322B2 (en) 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
ES2625905T3 (es) 2004-10-01 2017-07-20 Midatech Ltd. Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores
WO2006054806A1 (ja) 2004-11-22 2006-05-26 Locomogene, Inc. クローン病関連自己抗原
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070059775A1 (en) 2005-03-29 2007-03-15 The Trustees Of Columbia University In The City Of New York Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques
US7562421B2 (en) 2005-04-03 2009-07-21 Magen Eco Energy A.C.S. Ltd. Connecting clasp
US7326399B2 (en) 2005-04-15 2008-02-05 Headwaters Technology Innovation, Llc Titanium dioxide nanoparticles and nanoparticle suspensions and methods of making the same
US20090156480A1 (en) 2005-08-25 2009-06-18 Mitsuru Akashi Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein
ES2564241T3 (es) 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
DK2476436T3 (en) 2006-08-11 2018-02-05 Life Sciences Res Partners Vzw Immunogenic peptides and their use in immune disorders
US7816814B1 (en) 2006-08-18 2010-10-19 Hennessy Michael J Bi-directional power converters
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
CA2674632A1 (en) 2006-12-29 2008-07-10 University Of Washington Dual-functional nonfouling surfaces and materials
WO2008115641A2 (en) 2007-02-15 2008-09-25 Yale University Modular nanoparticles for adaptable vaccines
US8354110B2 (en) 2007-03-07 2013-01-15 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
US20140105980A1 (en) 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US20150250871A1 (en) 2007-03-07 2015-09-10 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2008118861A2 (en) 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Discrete size and shape specific organic nanoparticles designed to elicit an immune response
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009013741A2 (en) 2007-07-22 2009-01-29 Camtek Ltd Method and system for controlling a manufacturing process
JP5085240B2 (ja) 2007-09-03 2012-11-28 日本電波工業株式会社 水晶デバイス及び水晶デバイスの製造方法
US9295736B2 (en) 2007-09-24 2016-03-29 Bar Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
WO2009064273A1 (en) 2007-11-16 2009-05-22 Paul Appelbaum Apparatus and method for packaging articles in clear plastic packages
US8779088B2 (en) * 2007-12-17 2014-07-15 Marfl Ab Vaccine for the treatment of Mycobacterium related disorders
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
CA2717719A1 (en) 2008-02-04 2009-08-13 David G. Fernig Nanoparticle conjugates
JP2011525477A (ja) 2008-03-04 2011-09-22 リクイディア・テクノロジーズ・インコーポレーテッド 免疫調節剤粒子および処置方法
WO2009126835A2 (en) 2008-04-09 2009-10-15 University Of Washington Techtransfer Invention Licensing Magnetic nanoparticle and method for imaging t cells
US20090258355A1 (en) 2008-04-11 2009-10-15 Brookhaven Science Associates, Llc Nanoscale Clusters and Methods of Making Same
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
WO2010037397A1 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CA2642141A1 (en) 2008-10-20 2010-04-20 Innovative Microelectronics Inc. Flange alignment pin
CA2743590A1 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
SG193843A1 (en) 2009-01-20 2013-10-30 Univ Northwestern Compositions and methods for induction of antigen-specific tolerance
US8383085B2 (en) 2009-05-29 2013-02-26 University Of Manitoba Methods of making iron-containing nanoparticles
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
GB201003088D0 (en) 2010-02-24 2010-04-14 Univ Exeter Method for the preparation of a novel nanoparticle conjugate
NZ702796A (en) 2010-07-26 2017-03-31 Qu Biologics Inc Immunogenic anti-inflammatory compositions
JP6108112B2 (ja) 2010-08-25 2017-04-05 ラオ ダヴルリ，ラマモハン 改良されたルフィナミド調製プロセス
US20130171179A1 (en) 2010-09-03 2013-07-04 Oregon Health & Science University Recombinant t-cell receptor ligands with covalently bound peptides
KR101972291B1 (ko) 2010-09-29 2019-08-16 유티아이 리미티드 파트너쉽 생체적합성, 생흡수성 나노구를 사용하는 자가면역 질병의 치료방법
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
ES2627507T3 (es) 2011-09-07 2017-07-28 Midatech Ltd. Composiciones de nanopartícula-péptido
US20140251917A1 (en) 2011-09-22 2014-09-11 Marv Enterprises,LLC Method for the treatment of multiple sclerosis
EP2591801A1 (en) 2011-11-14 2013-05-15 Universitätsklinikum Hamburg-Eppendorf Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions
US20130128138A1 (en) 2011-11-18 2013-05-23 Shenzhen China Star Optoelectronics Technolog Co., LTD. Flat Panel Display Device, Stereoscopic Display Device, Plasma Display Device
US10758487B2 (en) 2011-12-09 2020-09-01 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20150150996A1 (en) 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
MX361076B (es) 2012-12-21 2018-11-27 Hoffmann La Roche Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
US9335768B2 (en) 2013-09-12 2016-05-10 Lam Research Corporation Cluster mass flow devices and multi-line mass flow devices incorporating the same
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
EP3160453A1 (en) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
WO2016145605A1 (zh) 2015-03-17 2016-09-22 王忠堂 一种便携式智能超声多普勒动态实时监测装置
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
BR112019009477A2 (pt) 2016-11-09 2019-07-30 Uti Lp moléculas de classe ii de pmhc recombinantes
SG11201909290TA (en) 2017-04-07 2019-11-28 Uti Lp Assay to measure the potency of receptor-ligand interactions in nanomedicines
US20200390856A1 (en) 2017-11-29 2020-12-17 Uti Limited Partnership Methods of treating autoimmune disease

Also Published As

Publication number Publication date
US10988516B2 (en) 2021-04-27
JP2019108399A (ja) 2019-07-04
WO2013144811A3 (en) 2013-11-28
CA2868551A1 (en) 2013-10-03
BR112014023859A8 (pt) 2018-01-16
EP3590531A1 (en) 2020-01-08
CA2868551C (en) 2021-07-27
CN110354278A (zh) 2019-10-22
US20130330414A1 (en) 2013-12-12
JP2015518467A (ja) 2015-07-02
CN104321077A (zh) 2015-01-28
MX2014011623A (es) 2015-02-12
PT2830654T (pt) 2019-09-23
RU2014141984A (ru) 2016-05-20
AU2016203231A1 (en) 2016-06-09
AU2016203231B2 (en) 2018-02-01
RU2689563C2 (ru) 2019-05-28
PL2830654T3 (pl) 2020-02-28
US20210230237A1 (en) 2021-07-29
CN110354278B (zh) 2023-05-02
JP6199955B2 (ja) 2017-09-20
AU2013202911A1 (en) 2013-10-10
WO2013144811A2 (en) 2013-10-03
IL234829B (en) 2019-09-26
EP2830654B1 (en) 2019-07-03
EP2830654A2 (en) 2015-02-04
DK2830654T3 (da) 2019-08-26
JP2018030842A (ja) 2018-03-01
JP6570082B2 (ja) 2019-09-04
IL234829A0 (en) 2014-12-31
BR112014023859A2 (pt) 2017-07-18
MX363000B (es) 2019-03-01
EP2830654B8 (en) 2019-08-07
ES2744491T3 (es) 2020-02-25
IL269166A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL269166A (en) Methods and preparations for treating inflammation
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
HK1209798A1 (en) Compositions and methods for treating cancer
EP2916876A4 (en) METHOD AND COMPOSITIONS FOR WOUND HEALING
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2890720A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
HK1251796A1 (zh) 治療糖尿病的方法和組合物
DK3292875T3 (en) Compositions and methods for treating diseases
HUE044816T2 (hu) Készítmények és eljárások hajhullás kezelésére
IL232648A0 (en) Preparations and methods for treating glioma
HK1208598A1 (en) Methods and compositions for treating pain
HK1216854A1 (zh) 用於治療癌症的組合物和方法
EP2863939A4 (en) COMPOSITIONS AND METHODS FOR TREATING VITILIGO
HK1211852A1 (en) Methods and compositions for treating progesterone-dependent conditions
EP2849778A4 (en) PROCESS FOR TREATMENT OF INFLAMMATION
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2822593A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2800763A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
EP2906199A4 (en) METHOD AND COMPOSITION FOR TREATING PSORIASIS
EP2718427A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLIOBLASTOMES